secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2022-01-31T23:59:59+00:00
Accession:  0001104659-22-009272
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec Pharmaceuticals CCO Shubh Goel resigns; effective late February
----------------------------------------------------------------------

- Shubh Goel, chief commercial officer, tendered resignation on Jan 31, 2022.
- Goel will depart in late February 2022.
- CEO Rosty Raykov thanked Goel for contributions; company continues launch preparations for PEDMARK.
- PEDMARK is a treatment for cisplatin-induced ototoxicity in pediatric patients, pending approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465922009272/0001104659-22-009272-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465922009272/tm224898d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-009272

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer